SCHEMBL25912147

SCHEMBL25912147

CN1CCC(n2cc3ccc(Br)cc3n2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.41
IRAK4 Q9NWZ3 4/20 0.40
HRH4 Q9H3N8 1/20 0.39
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
APP P05067 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
AXL P30530 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
BRAF P15056 2/20 0.34
MAPK3 P27361 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25911938 0.89 TLR8 (0.44) TLR8IRAK4HRH4HTTMEN1
SCHEMBL16595488 0.88 BACE1 (0.38) TLR8HTT
SCHEMBL3354874 0.83 KDM4E (0.54) TLR8IRAK4HRH4HTTMEN1
SCHEMBL28738106 0.82 BACE1 (0.34) TLR8IRAK4HTT
SCHEMBL25333810 0.82 TLR8 (0.31) TLR8HRH4HRH3
SCHEMBL26684084 0.81 KDM5A (0.40) IRAK4POLBKMT2AMAPK1
SCHEMBL31559923 0.81 IRAK4 (0.41) IRAK4HTT
SCHEMBL29082025 0.81 TLR8 (0.48) TLR8IRAK4
SCHEMBL19279754 0.81 BACE1 (0.33) TLR8HTT
SCHEMBL25323831 0.80 HRH3 (0.38) HRH4HTTMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
WO-2025215153-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2025-10-16 WO disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279219-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TLR8 2353/4885IRAK4 3901/4885HRH4 30/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 TLR8 2353/4885IRAK4 3901/4885HRH4 30/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TLR8 2353/4885IRAK4 3901/4885HRH4 30/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 TLR8 2684/4885IRAK4 4460/4885HRH4 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.